| |
| |
|
| Insider
Information: |
Kirk Randal J |
| Relationship: |
10% Owner |
| City: |
Radford |
| State: |
VA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
3,684,697 |
|
|
Indirect Shares
|
67,796,291 |
|
|
| Direct
Value |
$162,038,028 |
|
|
|
Indirect Value
|
$374,282,250 |
|
|
| Total
Shares |
71,480,988 |
|
|
| Total
Value |
$536,320,277 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
14
|
0
|
|
Stock
price went up :
|
6
|
0
|
| Stock
price went down : |
8
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 46.5%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Clinical Data Inc |
CLDA |
Director, 10% Owner |
2011-04-12 |
0 |
2011-04-12 |
0 |
Premium* |
|
|
Halozyme Therapeutics Inc |
HALO |
10% Owner |
2018-08-28 |
3,562,388 |
2018-08-28 |
6,629,464 |
Premium* |
|
|
Precipio Inc |
PRPO |
10% Owner |
2012-02-03 |
0 |
2018-08-28 |
27,151 |
Premium* |
|
|
Precigen Inc |
PGEN |
|
|
0 |
2024-05-02 |
51,557,665 |
Premium* |
|
|
Alaunos Therapeutics |
TCRT |
Director, 10% Owner |
2015-12-31 |
122,309 |
2015-12-31 |
9,570,094 |
Premium* |
|
|
Aquabounty Technologies, Inc. |
AQB |
10% Owner |
2020-02-13 |
0 |
2020-12-17 |
11,917 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
271 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 11
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2015-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,175 |
3,518,051 |
0 |
- |
|
| PGEN |
Precigen Inc |
Chief Executive Officer |
• • • |
2019-01-04 |
4 |
A |
$0.00 |
$0 |
I/I |
13,774 |
16,057,642 |
0 |
- |
|
| CLDA |
Clinical Data Inc |
Director |
– • • |
2006-08-28 |
4 |
B |
$15.07 |
$210,829 |
I/I |
13,990 |
557,642 |
2.25 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2017-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
14,135 |
3,552,388 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
10% Owner |
– – • |
2006-09-07 |
4 |
B |
$2.51 |
$37,650 |
I/I |
15,000 |
530,600 |
1.5 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2007-05-15 |
4 |
A |
$10.37 |
$155,550 |
D/D |
15,000 |
355,000 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2008-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
370,000 |
0 |
- |
|
| PGEN |
Precigen Inc |
Chief Executive Officer |
• • • |
2014-05-09 |
4 |
B |
$13.42 |
$202,481 |
I/I |
15,088 |
779,294 |
2.64 |
- |
|
| CLDA |
Clinical Data Inc |
Director |
– • • |
2010-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
15,200 |
2,326,687 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2007-09-18 |
4 |
B |
$8.87 |
$137,387 |
I/I |
15,489 |
3,946,915 |
2.25 |
- |
|
| TCRT |
Alaunos Therapeutics |
Director |
– • • |
2014-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
16,707 |
95,648 |
0 |
- |
|
| PGEN |
Precigen Inc |
Chief Executive Officer |
• • • |
2014-05-09 |
4/A |
B |
$13.42 |
$233,239 |
I/I |
17,248 |
129,794 |
2.64 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
10% Owner |
– – • |
2006-09-06 |
4 |
B |
$2.56 |
$44,288 |
I/I |
17,300 |
515,600 |
1.5 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
10% Owner |
– – • |
2006-08-22 |
4 |
B |
$2.46 |
$43,296 |
I/I |
17,600 |
204,400 |
1.5 |
- |
|
| CLDA |
Clinical Data Inc |
Director |
– • • |
2009-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
2,311,487 |
0 |
- |
|
| PGEN |
Precigen Inc |
Chief Executive Officer |
• • • |
2014-05-12 |
4 |
B |
$15.89 |
$287,069 |
I/I |
18,066 |
797,360 |
2.64 |
- |
|
| CLDA |
Clinical Data Inc |
Director |
– • • |
2008-09-23 |
4 |
A |
$0.00 |
$0 |
D/D |
18,334 |
1,639,280 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
10% Owner |
– – • |
2006-09-12 |
4 |
B |
$2.58 |
$51,600 |
I/I |
20,000 |
584,300 |
1.5 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
10% Owner |
– – • |
2006-09-14 |
4 |
B |
$2.50 |
$50,000 |
I/I |
20,000 |
678,300 |
1.5 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2009-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
3,390,000 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2010-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
3,410,000 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2011-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
3,430,000 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2012-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
3,450,000 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2013-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
3,470,000 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • • |
2016-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
20,202 |
3,538,253 |
0 |
- |
|
271 Records found
|
|
Page 2 of 11 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
